Recent developments highlight revenue growth, improved adjusted EBITDA, management changes, and analyst coverage initiation.

• Neuronetics reported a 9% increase in Q2 2026 revenue and adjusted EBITDA turned positive, with a narrowed outlook for 2026 [N7].
• The company reported a Q2 2026 loss but exceeded revenue expectations, reflecting operational progress [N6].
• Management changes include appointment of Nir Naor as CFO and promotion of Cory Anderson to Executive VP in mid-2026 [N7].
• B. Riley Securities initiated coverage of Neuronetics with a Buy rating in September 2026 [N3].
• Q2 2026 earnings call transcripts and highlights provide detailed insights into company performance and strategy [N4][N5].

The company has demonstrated revenue growth and improving adjusted EBITDA, indicating operational progress. Recent management appointments and analyst coverage initiation may support strategic execution. The combination of device sales and clinical services provides diversified revenue streams. Continued adoption of TMS therapy and expansion of clinical services could enhance business scale and financial performance.

Neuronetics continues to report net losses and negative earnings per share, reflecting challenges in achieving sustained profitability. The medical device and clinical services markets are competitive and subject to regulatory, reimbursement, and adoption risks. Liquidity, while currently adequate, requires ongoing management. Market acceptance and reimbursement for TMS therapy remain critical factors. Management transitions may introduce execution risks.

Neuronetics operates in the specialized medical device market for TMS therapy, which requires regulatory approvals, clinical validation, and specialized technology. Its NeuroStar Advanced Therapy System and clinical services segment provide a differentiated offering in the mental health treatment space. The company’s established presence, proprietary technology, and clinical service network contribute to competitive positioning. However, the medical device industry is competitive and subject to regulatory and reimbursement challenges.

• Profitability Risk: The company has reported net losses and negative EPS, indicating ongoing challenges in achieving profitability.
• Regulatory and Reimbursement Risk: Neuronetics operates in a regulated medical device market with reimbursement uncertainties that could impact adoption and revenue.
• Competitive Risk: The medical device and clinical services sectors are competitive, with risks from existing and new entrants.
• Liquidity Risk: While current liquidity ratios are strong, the company must manage cash flow to support operations and growth.
• Execution Risk: Management changes and strategic initiatives carry risks related to execution and market acceptance.

• Neuronetics, Inc. is a medical technology company focused on transcranial magnetic stimulation (TMS) therapy devices and clinical services.
• The company operates segments including NeuroStar Advanced Therapy Systems and Greenbrook TMS Inc.
• As of September 30, 2026, Neuronetics had cash and cash equivalents of $22.1 million and current assets of $53.9 million, with current liabilities of $26.9 million, resulting in a current ratio of 2.01 and a cash ratio of 0.82, indicating liquidity.
• For the quarter ended September 30, 2026, the company reported a net loss of $1.692 million and basic and diluted EPS of -$0.02 per share.
• The company reported revenue of $15.579 million for the fiscal year ended December 31, 2020, as per the latest available 10-K.
• Recent news includes Q2 2026 earnings call transcripts and highlights, reporting a 9% revenue increase and adjusted EBITDA turning positive, with a narrowed 2026 outlook.
• The company appointed Nir Naor as CFO and promoted Cory Anderson to Executive VP in mid-2026.
• B. Riley Securities initiated coverage of Neuronetics with a Buy rating in September 2026.
• The company has reported quarterly losses in recent periods but has shown revenue growth and improving adjusted EBITDA.
• The company has approximately 77.7 million shares outstanding as of October 28, 2026.
• The company is listed on the Nasdaq Global Market under the ticker STIM.
• The company filed all required SEC reports timely and is classified as a smaller reporting company and non-accelerated filer.
• The company’s business involves medical devices and clinical services related to TMS therapy, including treatment sessions and device sales.
• The company’s liquidity position as of September 30, 2026, shows a strong current ratio above 2, indicating sufficient short-term assets to cover liabilities.
• The company’s net losses and negative EPS reflect ongoing investment and operational costs relative to revenues.
• Recent developments include narrowing net losses and management changes including a new CEO appointed in early 2026.
• The company’s revenue growth and adjusted EBITDA improvement in Q2 2026 indicate operational progress.
• The company’s financial figures and disclosures are sourced from the latest SEC filings (10-K and 10-Q) and recent public news coverage.